Ok so lets try to clear up this uncertainty
As in
Yes, most of us here quite confused about the Non-Clinical Requirement... But if you try to read through from the above-mentioned links, you are probably clear your doubt a bit..
So in actual fact
Animal Studies (also called nonclinical data).
studies that provide the first data
to support the Initial safety in
testing humans
Partial clinical hold.
The proposed trial may proceed only with restrictions that FDA will
describe in their letter to the sponsor.
If FDA places your IND on a clinical hold,
The Company would work with the FDA to resolve the deficiencies.
They should prepare and submit a response to the critical issues that led to
the clinical hold.
There may be a need to submit additional NONE CLINICAL DATA
explain existing data, or modify the protocol to ensure patient
safety
ATL1102 as far as the FDA is concerned is in a partial hold with a max dosing of 25mg this is an issue they obviously have to address
I am not saying we are not going to move forwards in our trials
But unlike others here that believed one trip to the FDA and it would be plain sailing obviously, not going to be that simple
People ask for facts but but when facts are presented some folks find them hard to swallow
I tend to research not what is said in ASX Ann but what is not said in these Ann
Optimistic pessimistic realistic
The facts are the facts and ANP have a few issues to work through, which is all i have ever stated,
I got from that ANP Ann all i was expecting,
Guidance for ANP to move forwards into into the Ph2b 3 trial which i am sure they will get on what sort of a time frame remains to be seen
Enjoy your Wkends
I will be at the bottom of my driveway tomorrow morning
![]()
- Forums
- ASX - By Stock
- PER
- Ann: US FDA Type C Meeting for ATL1102 in DMD
Ann: US FDA Type C Meeting for ATL1102 in DMD, page-58
-
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.0¢ |
Change
-0.001(1.23%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.2¢ | 8.2¢ | 8.0¢ | $63.52K | 777.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 43377 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 97561 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 43377 | 0.080 |
2 | 212658 | 0.078 |
1 | 200000 | 0.077 |
3 | 91500 | 0.076 |
4 | 206988 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 97561 | 1 |
0.083 | 214000 | 1 |
0.084 | 67142 | 2 |
0.085 | 141000 | 2 |
0.086 | 106100 | 2 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |